These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19692771)

  • 1. [Survey of oxaliplatin-associated peripheral sensory neuropathy using an interview-based questionnaire in patients with advanced colorectal cancer].
    Satomi M; Kono T; Mamiya N; Chisato N; Ebisawa Y; Sugawara M; Saito T; Matsubara K; Kasai S
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1321-5. PubMed ID: 19692771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].
    Matsuo K; Higuchi M; Sasaki Y; Iwatsubo S; Wada Y; Hasegawa K; Shirakawa A; Mishima K; Iwasaki K; Fujiwara M; Nishino H
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):551-4. PubMed ID: 20332703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
    Inoue N; Ishida H; Sano M; Kishino T; Okada N; Kumamoto K; Ishibashi K
    Int J Clin Oncol; 2012 Aug; 17(4):341-7. PubMed ID: 21833683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
    Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
    Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
    Matsuda M; Matsusaka S; Kuboki Y; Itimura T; Ogura M; Suenaga M; Syouji D; Watanabe C; Chin K; Mizunuma N; Hatake K
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):461-6. PubMed ID: 18347395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
    Shindo Y; Tenma K; Imano H; Hibino M; Yoshino K; Nakamura M
    Gan To Kagaku Ryoho; 2008 May; 35(5):863-5. PubMed ID: 18487931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of oxaliplatin-induced neuropathy: a patient perspective.
    Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
    Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.
    Choi J; Kong K; Mozaffar T; Holcombe RF
    Anticancer Drugs; 2006 Jan; 17(1):103-5. PubMed ID: 16317297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
    Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
    Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.
    von Delius S; Eckel F; Wagenpfeil S; Mayr M; Stock K; Kullmann F; Obermeier F; Erdmann J; Schmelz R; Quasthoff S; Adelsberger H; Bredenkamp R; Schmid RM; Lersch C
    Invest New Drugs; 2007 Apr; 25(2):173-80. PubMed ID: 16983507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma].
    Nagahara H; Noda E; Maeda K; Inoue T; Hirakawa T; Hasegawa T; Shibutani M; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1181-3. PubMed ID: 24047775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.